RE: The future11 Jun 2026 15:50
MM you seem to bang on about Avion being in charge here, they are not. Nobody here has seen the actual legal text in full, but it will cover the full scope of the original deal and within that as part of any signing of a MOU or contract will have get out clauses. What we do know is what Avion agreed to fund and how much for, chiefly $25M Phase 3 of lupozor for the treatment of Lupus (years have passed and no P3, pharma contracts have time limits). P140 the rebrand has a new patent submitted and is now a multi platform diagnostic and treatment well outside the original scope and estimated to cost $100M in a phase 3. So Avion even if they wanted to, cannot afford to take this into trials and equally this deal does not suit either party. The fact that IMM are brazenly speaking to other partners suggests Avion will be paid off on any deal announcement, it will likely be a negligible amount in the grand scheme of any deal. It's either that or they have to take IMM to court for breach of contract, which they will likely lose because as already pointed out P140's intended purpose is far beyond Lupozor. They also hold shares so any big deal sees those shares increasing exponentially in value.
I'm not even a holder anymore but as an occasional reader of this BB your posts are not only repetitive but out of touch on how pharma acquisitions work. If big pharma wants a treatment or drug, then minnows, small, mediums often fold beneath them. IMM won't be sweating if it came to a legal battle because it won't but if it did and it was Pfizer, AstraZeneca or Roche you'd back their legal teams over Alora Pharmaceuticals.